Articles

Crystal-clear acquisitions

Corning Life Sciences to further broaden offerings with acquisition of majority of BD Discovery Labware
Written byJeffrey Bouley
| 5 min read

CORNING, N.Y.—Although a quick look through your kitchencabinets will probably yield all sorts of evidence of Corning Inc.'s prominencein your life, many forget that the company's business spans many industries,especially high-tech ones—among them life sciences. That aspect of the businessgot the prospect of a big boost April 10 with the announcement that Corning hasreached a definitive agreement with BD (Becton, Dickinson and Co.) to acquirethe majority of its Discovery Labware unit for approximately $730 million incash.

The acquisition is expected to be complete later this year,subject to customary closing conditions, including receipt of regulatoryapprovals.

"The Discovery Labware unit's extensive product portfolioand established dealer network will significantly improve Corning LifeSciences' offerings to customers and is a critical part of Corning's long-termgrowth strategy," said Wendell P. Weeks, chairman, CEO and president ofCorning, in the news release about the deal. "With sales of approximately $235million, the acquisition will expand Corning Life Sciences' annual revenues by40 percent and catapult the segment toward its goal of being a $1 billionbusiness by 2014. And, the acquisition provides added momentum for Corning toachieve our $10 billion revenue target in the next few years."

While the company is far from floundering, life sciencesrepresents an important growth segment to offset lagging activity in otherareas, such as a drop in demand for flat-screen televisions. In 2011, forexample, profits at Corning's display technologies unit fell more than 20percent to $2.3 billion, which drove down overall profits, even though revenuehad increased to a record $7.9 billion.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.